Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Corporate VC Funds Drive Innovation For Aileron’s Novel Stapled Peptide Technology

This article was originally published in The Pink Sheet Daily

Executive Summary

Aileron’s stapled peptides spark investment interest from four big pharma VC arms.

You may also be interested in...



Aileron Raises $30M From Existing Investors To Advance Pair Of Stapled Peptide Candidates

The Cambridge, Mass., biotech plans to bring a candidate for cancer into clinical development next year, while starting Phase Ib dose-finding research with its endocrinology disorder candidate.

Roche Partners With Peptide Specialist Aileron For Five Targets

A $25 million upfront commitment could blossom into a deal worth as much as $1.1 billion plus royalties.

Roche Partners With Peptide Specialist Aileron For Five Targets

A $25 million upfront commitment could blossom into a deal worth as much as $1.1 billion plus royalties.

Related Content

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel